SIMTRA
Live / Applied — Third extension granted (statement of use) (as of 27 Jan 2026)
What this means for you
Not registered yet, but its 07 Sept 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98169997
- Mark type
- Stylized text
- Filed
- 07 Sept 2023
- Published for opposition
- 18 Jun 2024
- Attorney of record
- Salima A. Merani
Goods and services
- Class 001 — Chemicals: Active chemical ingredients for use in the manufacture of pharmaceuticals for treating cancer, infectious diseases, immune disorders, infertility, viruses, blood disorders, genetic disorders, digestive disorders, inflammation, diabetes-related conditions, viral conditions, metabolic conditions, endocrine conditions, musculoskeletal conditions, cardiovascular conditions, cardiopulmonary conditions, genitourinary conditions, sexual dysfunction, hepatological conditions, ophthalmic conditions, respiratory conditions, gastrointestinal conditions, hormonal conditions, degenerative disorders, and dermatological conditions; Chemical additives for use in the manufacture of pharmaceuticals; Chemical additives for use in the manufacture of a wide variety of goods; Chemical preparations for scientific purposes; Chemicals for use in industry and science
- Class 005 — Pharmaceuticals: Dermatologicals; Inhalers for medical purposes, sold filled with pharmaceutical preparations for treating respiratory disorders, infectious disorders, infertility, viruses, diabetes-related conditions, cancer, immune conditions and inflammation; Medicated cosmetics; Medicated dermatological preparations and substances; Pharmaceutical preparations for the treatment and prevention of cancer, infectious diseases, immune disorders, infertility, viruses, blood disorders, genetic disorders, digestive disorders, inflammation, diabetes-related conditions, viral conditions, metabolic conditions, endocrine conditions, musculoskeletal conditions, cardiovascular conditions, cardiopulmonary conditions, genitourinary conditions, sexual dysfunction, hepatological conditions, ophthalmic conditions, respiratory conditions, gastrointestinal conditions, hormonal conditions, degenerative disorders and dermatological conditions; Syringes sold filled with pharmaceutical preparations for treating respiratory disorders, infectious disorders, infertility, viruses, diabetes-related conditions, cancer, immune conditions and inflammation
- Class 040 — Treatment of materials: Custom manufacture of pharmaceuticals; Manufacturing services for others in the field of pharmaceuticals; Providing technical information in the field of pharmaceutical manufacturing
- Class 042 — Scientific and technological services: Consulting services in the field of pharmaceutical research and development; Pharmaceutical drug development services; Pharmaceutical products development; Pharmaceutical research services; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Testing of pharmaceuticals
- Class 044 — Medical, beauty and agricultural services: Pharmaceutical advice; Pharmaceutical compounding services; Providing medical information to manufacturers in the form of reports in the field of manufacturing of active ingredients and scaling
Owner
- BAMBOO US BIDCO LLC, New York, NY, US
- BAMBOO US BIDCO LLC, New York, NY, US
Prosecution history
- 28 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 Jan 2026 — SOU EXTENSION 3 GRANTED
- 27 Jan 2026 — SOU EXTENSION 3 FILED
- 27 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 08 Aug 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 07 Aug 2025 — SOU EXTENSION 2 GRANTED
- 07 Aug 2025 — SOU EXTENSION 2 FILED
- 07 Aug 2025 — SOU TEAS EXTENSION RECEIVED
- 04 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Feb 2025 — SOU EXTENSION 1 GRANTED
- 04 Feb 2025 — SOU EXTENSION 1 FILED
- 03 Feb 2025 — SOU TEAS EXTENSION RECEIVED
- 13 Aug 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 18 Jun 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 18 Jun 2024 — PUBLISHED FOR OPPOSITION